WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.

TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its development of innovative ...

Executive Summary TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a ...

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...

(RTTNews) - TScan Therapeutics, Inc. (TCRX) announced on Monday that Chrystal Louis has been appointed as the chief medical officer. Louis will succeed Debora Barton, who has held the position since ...

Potential TScan Therapeutics, Inc. (NASDAQ:TCRX) shareholders may wish to note that the Chairman of the Board, Timothy Barberich, recently bought US$142k worth of stock, paying US$4.89 for each share.

TScan’s presentation focused on two main programs: its hematologic malignancies (HEME) program, which has shown promising Phase 1 data, and its solid tumor program utilizing a multiplex approach. The ...